although some tumor inhibition was also produced by unlabeled 250-30.6 antibody , this response was considerably amplified by treatment with [ 131i ] -labeled 250-30.6 ( p less than .05 ) , suggesting that in vivo treatment of human tumors with the use of 131i-labeled monoclonal antibodies may be clinically beneficial .
C0003241
antibody
C0003250
monoclonal antibodies